AR051381A1 - Derivados de ariltiobencilpiperidina - Google Patents
Derivados de ariltiobencilpiperidinaInfo
- Publication number
- AR051381A1 AR051381A1 ARP050104233A ARP050104233A AR051381A1 AR 051381 A1 AR051381 A1 AR 051381A1 AR P050104233 A ARP050104233 A AR P050104233A AR P050104233 A ARP050104233 A AR P050104233A AR 051381 A1 AR051381 A1 AR 051381A1
- Authority
- AR
- Argentina
- Prior art keywords
- straight
- branched
- inclusive
- residue
- integer
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 101150104680 MCH1 gene Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de ariltiobencilpiperidina los cuales son ligandos del receptor de MCH1. La presente provee una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de formula (1) y de un portador farmacéuticamente aceptable. También provee una composicion farmacéutica elaborada mediante la mezcla de una cantidad terapéuticamente efectiva de un compuesto de formula (1) y un portador farmacéuticamente aceptable. Provee además un proceso para elaborar una composicion farmacéutica que comprende la combinacion de una cantidad terapéuticamente efectiva de un compuesto de formula (1) y un portador farmacéuticamente aceptable. Y el uso para el tratamiento de depresion, ansiedad y obesidad. Reivindicacion 1: Un compuesto que tiene la estructura en donde cada X1, X2, X3, X4 y X5 es independientemente CR1 o N, siempre que si una X es N entonces las X restantes son cada una CR1; en donde cada U1, U2, U3 y U4 es independientemente CH o N, siempre que si una U es N entonces las U restantes son cada una CH; en donde cada Y1, Y2, Y3 e Y4 es independientemente CR7 o N, siempre que si una Y es N entonces las Y restantes son cada una CR7; en donde G es H o -C(O)D; en donde D es un resto del grupo de formulas (2) en donde Z es -N(R5) o -O-; en donde cada A es independientemente H o alquilo C1-4 de cadena recta o ramificado; en donde B es CH o N; en donde cada R1 es independientemente H, alquilo C1-7 de cadena recta o ramificado, fluoralquilo C1- 7 de cadena recta o ramificado, alcoxi C1-7 de cadena recta o ramificado, F, Cl, Br o I; en donde R2 es H o alquilo C1-4 de cadena recta o ramificado; en donde R3 es H o alquilo C1-4 de cadena recta o ramificado; o en donde si B es N, entonces el residuo R2, B, el residuo R3 y un enlace formado entre el residuo R2 y el residuo R3 forman un resto de formulas (3) o en donde si B es CH, entonces el residuo R2, B, el residuo R3 y un enlace formado entre el residuo R2 y el residuo R3 forman ciclopropilo, ciclobutilo, ciclopentilo o ciclohexilo; en donde R4 es H, alquilo C1-4 de cadena recta o ramificado, fluoralquilo C1-4 de cadena recta o ramificado o F; en donde R5 es H o alquilo C1-4 de cadena recta o ramificado; en donde cada R6 es independientemente alquilo C1-7 de cadena recta o ramificada, fluoralquilo C1-7 de cadena recta o ramificado, alcoxi C1-7 de cadena recta o ramificado, F, Cl, Br o I; en donde cada R7 es independientemente H, alquilo C1-7 de cadena recta o ramificado, fluoralquilo C1-7 de cadena recta o ramificado, alcoxi C1-7 de cadena recta o ramificado, F, Cl, Br o I; en donde R8 es H, alquilo C1-4 de cadena recta o ramificado, fluoralquilo C1-4 de cadena recta o ramificado o F; en donde m es un entero desde 0 hasta 4 inclusive; en donde n es un entero desde 0 hasta 2 inclusive; en donde p es un entero desde 0 hasta 4 inclusive; en donde q es un entero desde 0 hasta 3 inclusive; en donde r es 1 o 2; en donde s es un entero desde 0 hasta 4 inclusive; en donde t es un entero desde 2 hasta 4 inclusive; en donde v es un entero desde 0 hasta 2 inclusive; y en donde w es un entero desde 1 hasta 5 inclusive; o una de las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/961,432 US20060079683A1 (en) | 2004-10-08 | 2004-10-08 | Arylthiobenzylpiperidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051381A1 true AR051381A1 (es) | 2007-01-10 |
Family
ID=36146248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104233A AR051381A1 (es) | 2004-10-08 | 2005-10-07 | Derivados de ariltiobencilpiperidina |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060079683A1 (es) |
| EP (1) | EP1799223A4 (es) |
| JP (1) | JP2008515887A (es) |
| CN (1) | CN101048161A (es) |
| AR (1) | AR051381A1 (es) |
| WO (1) | WO2006041635A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2539306A1 (en) * | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
| WO2009041567A1 (ja) * | 2007-09-27 | 2009-04-02 | Banyu Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体 |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| CN115626922A (zh) * | 2021-04-29 | 2023-01-20 | 苏州恩华生物医药科技有限公司 | 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-醇衍生物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1389189A2 (en) * | 2001-05-22 | 2004-02-18 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| US6727264B1 (en) * | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| US7199135B2 (en) * | 2001-07-05 | 2007-04-03 | H. Lundbeck A/S | Substituted alkyl amido piperidines |
| UA77536C2 (en) * | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
-
2004
- 2004-10-08 US US10/961,432 patent/US20060079683A1/en not_active Abandoned
-
2005
- 2005-09-21 WO PCT/US2005/033870 patent/WO2006041635A2/en not_active Ceased
- 2005-09-21 CN CNA2005800337442A patent/CN101048161A/zh active Pending
- 2005-09-21 JP JP2007535696A patent/JP2008515887A/ja not_active Withdrawn
- 2005-09-21 EP EP05806054A patent/EP1799223A4/en not_active Withdrawn
- 2005-10-07 AR ARP050104233A patent/AR051381A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006041635A3 (en) | 2007-04-05 |
| CN101048161A (zh) | 2007-10-03 |
| EP1799223A4 (en) | 2008-01-23 |
| EP1799223A2 (en) | 2007-06-27 |
| JP2008515887A (ja) | 2008-05-15 |
| WO2006041635A2 (en) | 2006-04-20 |
| WO2006041635A8 (en) | 2007-05-18 |
| US20060079683A1 (en) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| PE20240886A1 (es) | Compuestos espirociclicos | |
| AR049708A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| PE20060932A1 (es) | Derivados de sulfonamidas como moduladores de receptores de glucocorticoides (gr) | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| UY28374A1 (es) | Agentes terapéuticos | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR063636A1 (es) | Derivados de indol y de benzofurano-2-carboxamida | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
| CO5601030A2 (es) | Derivados de quinolinona/benzoxazinona y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |